Prostacyclin in the intensive care setting

被引：28

作者：

Ivy, D. Dunbar ^{[1
]}

机构：

[1] Univ Colorado, Denver Sch Med, Dept Pediat, Childrens Hosp, Aurora, CO USA

来源：

PEDIATRIC CRITICAL CARE MEDICINE | 2010年 / 11卷

基金：

美国国家卫生研究院;

关键词：

epoprostenol; treprostinil; iloprost; pulmonary arterial hypertension; congenital heart disease; critical care; PULMONARY-ARTERIAL-HYPERTENSION; INHALED ILOPROST THERAPY; LONG-TERM TREATMENT; INTRAVENOUS EPOPROSTENOL; AEROSOLIZED ILOPROST; TREATMENT FAILURE; NITRIC-OXIDE; DOUBLE-BLIND; TREPROSTINIL; CHILDREN;

D O I：

10.1097/PCC.0b013e3181d10845

中图分类号：

R4 [临床医学];

学科分类号：

100218 [急诊医学];

摘要：

The prostacyclins-prostanoids were one of the first medications used to treat pulmonary arterial hypertension (PAH). Three prostanoids have been developed to treat PAH: epoprostenol, treprostinil, and iloprost. In the acute setting, experience is growing, using the inhaled forms of these three medications. Inhalation may improve ventilation/perfusion matching, whereas in the intravenous form these medications may cause nonselective pulmonary vasodilation and may worsen ventilation/perfusion matching. Currently, there are no universal recommendations for dosing delivery of inhaled prostanoids to intubated patients in the intensive care unit setting. (Pediatr Crit Care Med 2010; 11[Suppl.]:S41-S45)

引用

页码：S41 / S45

页数：5

共 52 条

[1]

THROMBOXANE-A(2) AND PROSTACYCLIN BIOSYNTHESIS IN CHILDREN AND ADOLESCENTS WITH PULMONARY VASCULAR-DISEASE [J].

ADATIA, I ;

BARROW, SE ;

STRATTON, PD ;

MIALLALLEN, VM ;

RITTER, JM ;

HAWORTH, SG .

CIRCULATION, 1993, 88 (05) :2117-2122

[2]

Medical therapy for pulmonary arterial hypertension - Updated ACCP evidence-based clinical practice guidelines [J].

Badesch, David B. ;

Abman, Steven H. ;

Simonneau, Gerald ;

Rubin, Lewis J. ;

McLaughlin, Vallerie V. .

CHEST, 2007, 131 (06) :1917-1928

[3]

Prostanoid therapy for pulmonary arterial hypertension [J].

Badesch, DB ;

McLaughlin, VV ;

Delcroix, M ;

Vizza, CD ;

Olschewski, H ;

Sitbon, O ;

Barst, RJ .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (12) :56S-61S

[4]

Barst R., 2007, Morbidity and Mortality Weekly Report, V56, P170

[5]

Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil [J].

Barst, R. J. ;

Galie, N. ;

Naeije, R. ;

Simonneau, G. ;

Jeffs, R. ;

Arneson, C. ;

Rubin, L. J. .

EUROPEAN RESPIRATORY JOURNAL, 2006, 28 (06) :1195-1203

[6]

Vasodilator therapy for primary pulmonary hypertension in children [J].

Barst, RJ ;

Maislin, G ;

Fishman, AP .

CIRCULATION, 1999, 99 (09) :1197-1208

[7]

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension [J].

Barst, RJ ;

Rubin, LJ ;

Long, WA ;

McGoon, MD ;

Rich, S ;

Badesch, DB ;

Groves, BM ;

Tapson, VF ;

Bourge, RC ;

Brundage, BH ;

Koerner, SK ;

Langleben, D ;

Keller, CA ;

Murali, S ;

Uretsky, BF ;

Clayton, LM ;

Jobsis, MM ;

Blackburn, SD ;

Shortino, D ;

Crow, JW .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (05) :296-301

[8]

Beraprost therapy for pulmonary arterial hypertension [J].

Barst, RJ ;

McGoon, M ;

McLaughlin, V ;

Tapson, V ;

Oudiz, R ;

Shapiro, S ;

Robbins, IM ;

Channick, R ;

Badesch, D ;

Rayburn, BK ;

Flinchbaugh, R ;

Sigman, J ;

Arneson, C ;

Jeffs, R .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (12) :2119-2125

[9]

SURVIVAL IN PRIMARY PULMONARY-HYPERTENSION WITH LONG-TERM CONTINUOUS INTRAVENOUS PROSTACYCLIN [J].

BARST, RJ ;

RUBIN, LJ ;

MCGOON, MD ;

CALDWELL, EJ ;

LONG, WA ;

LEVY, PS .

ANNALS OF INTERNAL MEDICINE, 1994, 121 (06) :409-415

[10]

Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension [J].

Channick, Richard N. ;

Olschewski, Horst ;

Seeger, Werner ;

Staub, Ted ;

Voswinckel, Robert ;

Rubin, Lewis J. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 48 (07) :1433-1437

← 1 2 3 4 5 6 →